NTLA Stock Recent News
NTLA LATEST HEADLINES
Artificial intelligence stocks will be the choice of growth-oriented investors for years to come. But if you're a buy-and-hold investor with above-average patience, this is a time to look for undervalued gene editing stocks.
Intellia Therapeutics makes gene editing therapies. Some of those therapies could theoretically cure certain patients.
OAKDALE, Minn.--(BUSINESS WIRE)--BlueAllele® Corporation, a biotechnology company focused on advancing transformational gene editing technologies, filed a patent infringement lawsuit against Intellia Therapeutics in the United States District Court for the District of Delaware. The complaint alleges infringement of BlueAllele's bi-directional insertion template patents, which cover the company's transformational platform used in the development and treatment of genetic diseases. The novel desig.
Let's get down to it: why should investors consider pharma stocks? Primarily, it comes down to the permanence of the underlying narrative.
Investing in biotech can be pretty unpredictable. Biotech stocks are highly volatile, and picking carefully can be the difference between losing all your capital and making unimaginable profits.
NEW YORK , July 2, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Intellia Therapeutics, Inc. (NASDAQ: NTLA) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
Wood added to her positions in Palantir, Archer Aviation, and Intellia Therapeutics on Monday. Palantir is one of her largest holdings, and the big data analytics specialist has more than quadrupled since the start of last year.
Searching for quality undiscovered biotech stocks can be a bit like a treasure hunt. The biotech scene is full of intriguing innovators trying to progress their treatments through various clinical trials.
With the progression of modern medicine, and the continuous discoveries in the realm of gene editing, investing early in the technology could be a game changer for long-term returns if selecting the best gene editing stocks to buy. That's because unlike more standard therapeutics such as antibiotics, antivirals and vaccines gene editing is a permanent solution most of the time.
3 Biotech Stocks For The Second Half Of 2024